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Abstract
Background: The microenvironment plays a pivotal role in tumor cell proliferation, survival and migration. Invasive cancer
cells face a new set of environmental challenges as they breach the basement membrane and colonize distant organs
during the process of metastasis. Phenotypic switching, such as that which occurs during epithelial-mesenchymal transition
(EMT), may be associated with a remodeling of cell surface receptors and thus altered responses to signals from the tumor
microenvironment.
Methodology/Principal Findings: We assessed changes in intracellular Ca
2+ in cells loaded with Fluo-4 AM using a
fluorometric imaging plate reader (FLIPR
TETRA) and observed significant changes in the potency of ATP (EC50 0.175 mM
(2EGF) versus 1.731 mM( +EGF), P,0.05), and the nature of the ATP-induced Ca
2+ transient, corresponding with a 10-fold
increase in the mesenchymal marker vimentin (P,0.05). We observed no change in the sensitivity to PAR2-mediated Ca
2+
signaling, indicating that these alterations are not simply a consequence of changes in global Ca
2+ homeostasis. To
determine whether changes in ATP-mediated Ca
2+ signaling are preceded by alterations in the transcriptional profile of
purinergic receptors, we analyzed the expression of a panel of P2X ionotropic and P2Y metabotropic purinergic receptors
using real-time RT-PCR and found significant and specific alterations in the suite of ATP-activated purinergic receptors
during EGF-induced EMT in breast cancer cells. Our studies are the first to show that P2X5 ionotropic receptors are enriched
in the mesenchymal phenotype and that silencing of P2X5 leads to a significant reduction (25%, P,0.05) in EGF-induced
vimentin protein expression.
Conclusions: The acquisition of a new suite of cell surface purinergic receptors is a feature of EGF-mediated EMT in MDA-
MB-468 breast cancer cells. Such changes may impart advantageous phenotypic traits and represent a novel mechanism for
the targeting of cancer metastasis.
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Introduction
Epithelial-mesenchymal transition (EMT) is a pathway implicat-
ed incancermetastasis.[1].Thisprocess involvesthedegradation of
cell-cell and cell-extracellular matrix adhesions and the subsequent
down-regulation of junctional proteins such as E-cadherin [1,2].
Cells undergo a re-organization of the cytoskeleton and production
of the type III intermediate filament vimentin [3]. These alterations
are associated with a change in cell shape, from an epithelial to a
mesenchymal or fibroblast-like morphology [4,5].
Cancer cells are dependent upon extracellular cues from the
tumor microenvironment [6], such as epidermal growth factor
(EGF), which can promote breast cancer cell migration [7].
Goswami et al [8] have described an in vivo paracrine loop whereby
colony-stimulating-factor-1 (CSF-1) expressing cancer cells recruit
tumor-associated macrophages, which then secrete EGF, promot-
ing cancer cell elongation and migration. In vitro some cell lines
undergo EMT in response to EGF stimulation [4], such as the
human breast cancer cell line MDA-MB-468.
Once converted to a migratory phenotype, cancer cells face a
new set of environmental challenges. For example, the circulatory
system and secondary tumor microenvironment may not be
conducive to cell growth and survival. Cellular remodeling
occurring as a consequence of EMT, whereby cells have altered
responses to agents in the circulatory system or secondary tumor
site, could be advantageous for the process of metastasis [9,10].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23464A remodeling of cells, the consequence of which is an altered
response to external stimuli, occurs in vascular smooth muscle
cells, which convert from a contractile to a proliferative phenotype
[11,12]. Conversion of vascular smooth muscle cells to a
proliferative phenotype is an important mechanism in vasculature
repair but can also contribute to vascular disease [11]. The
proliferative phenotype of vascular smooth muscle cells has
alterations in the nature of responses to G-protein coupled
receptor activators, such as angiotensin II, thrombin and
vasopressin [13]. However, few studies have evaluated if analogous
alterations in cell surface receptor-mediated signaling also occurs
during the phenotypic switch associated with EMT in cancer cells.
Many cell surface receptors, including some receptor tyrosine
kinases, G-protein coupled receptors, and ligand-gated ion
channels signal via changes in cytosolic Ca
2+ concentrations.
Calcium is an important intracellular signaling molecule and
regulates a diverse range of physiological and pathological
processes [14,15]. For example, the Ca
2+-related proteins Orai1
and STIM1, important for store operated calcium entry pathways,
are important in breast cancer cell migration and metastasis [16].
Two external stimuli that are important in breast cancer cells
and elicit an intracellular Ca
2+ response are serine proteases and
adenosine 59-triphosphate (ATP). Serine proteases activate the
protease activated receptor (PAR) family of plasma membrane
receptors [17]. PAR2 is a G-protein-coupled receptor that
undergoes proteolytic cleavage and activation following exposure
to the serine protease trypsin [18]. Activation of PAR2 triggers an
intracellular signaling cascade downstream of phospholipase C
activation, which results in the production of IP3 and the
mobilization of Ca
2+ from intracellular stores [19]. PAR2 silencing
in the mesenchymal-like cell line MDA-MB-231 [20] inhibits cell
migration [19]. The coagulant proteases VIIa and Xa are
endogenous ligands for the PAR2 receptor; these coagulation
proteins stimulate migration in human breast cancer cells via
PAR2 activation [19]. ATP can also act as an external paracrine
factor and tumor promoter, via its effects on P2X non-selective
cation channels and P2Y metabotropic purinergic receptors [21].
Activation of these receptors results in elevation of cytosolic Ca
2+
via influx (P2X) [22] and store-release (P2Y) mechanisms [23].
ATP is released in the micromolar concentration range in the
tumor environment [24] and ATP increases proliferation of MCF-
7 human breast cancer cells via Ca
2+-dependent PI3K/Akt
pathways downstream of P2Y2 and/or P2Y4 purinergic receptors
[25].
In these studies we investigated whether EGF-induced EMT is
associated with a remodeling of receptor isoforms to external
stimuli. Consequent changes in intracellular Ca
2+ signaling may
help cells better meet the demands associated with metastasis.
Results
Changes in sensitivity to ATP
As previously described [4], MDA-MB-468 cells treated with
EGF (50 ng/mL) had elevated levels of the mesenchymal marker
vimentin after 24 h (Fig. 1 A & B) and a gradual decrease in the
epithelial protein E-cadherin after 72 h (Fig. 1B). We also assessed
the effect of EGF (50 ng/mL, 24 h) on Ca
2+ signaling in MDA-
MB-468 cells. While we saw no significant difference in the
potency for PAR2 activation with trypsin we did observe a 10-fold
statistically significant (P,0.05) shift in the potency for ATP
compared to control cells (EC50 1.731 mM and 0.175 mM,
respectively) (Fig. 1C). This suggests that EGF can induce specific
changes in the response to some extracellular stimuli including
ATP. To investigate this effect further we examined the differential
response and mechanism of ATP signaling associated with EGF-
mediated EMT in MDA-MB-468 breast cancer cells.
Changes in the nature of ATP-induced Ca
2+ transients
In addition to a change in agonist potency we observed a
significant difference in the nature of the Ca
2+ profile associated
with ATP stimulation. Treatment with EGF for 24 h altered the
post-peak decay kinetics in MDA-MB-468 cells stimulated with a
range of ATP concentrations (Fig. 2). Cells exposed to EGF
exhibited a faster return to baseline cytosolic Ca
2+ levels than
those in the absence of EGF.
To assess the time dependence of this effect MDA-MB-468 cells
were treated with EGF for 1, 6, 12 and 24 h prior to analysis of
ATP-mediated increases in [Ca
2+]CYT (Fig. 3A). At 1 and 6 h post
EGF treatment, the ATP-induced Ca
2+ transients were unchanged
and similar to those of control cells. However, modest alterations
in the decay kinetics were apparent as early as 12 h following EGF
exposure. At 24 h pronounced differences in the peak relative
[Ca
2+]CYT and decay kinetics of the [Ca
2+]CYT transient mediated
by ATP were evident; this effect corresponded to a significant
increase in vimentin protein expression (Fig. 3B).
EGF-induced alterations in the ATP response are not a
consequence of the loss of cell-cell adhesion associated
with EMT
A defining feature of EMT is a change in cell morphology and
loss of cell-cell contacts [26]. Given that gap junctions facilitate
inter-cellular communication by permitting the passage of Ca
2+
ions and IP3 between neighboring cells [27], alterations in the
nature of the [Ca
2+]CYT signal elicited by ATP could be due to
EGF-induced loss of inter-cellular communication. To assess this
we measured [Ca
2+]CYT in non-adherent MDA-MB-468 breast
cancer cells. In suspended cells EGF treatment produced the same
change in the ATP dose response curve (Fig. 4A) and the nature of
the [Ca
2+]CYT transient (Fig. 4B & C) as seen in the adherent cells
(Fig. 2). This suggests that alterations in the response to ATP in
cells treated with EGF are not a consequence of the loss of cell-cell
contacts associated with EMT.
EGF induces a switch in the purinergic receptor profile of
MDA-MB-468 breast cancer cells
Another possible explanation for changes in ATP-mediated
Ca
2+ signaling may be due to alterations in the purinergic receptor
profile in MDA-MB-468 cells as a consequence of EGF-
stimulation. To investigate if changes in the transcription of
purinergic receptors precede EMT, we analyzed the expression of
a bank of purinergic receptors using real-time RT-PCR. Seven
P2X (P2X1–7) and eight P2Y (P2Y1, 2, 4, 6, 11–14) receptor isoforms
were studied in MDA-MB-468 cells stimulated with EGF.
Changes in transcription were assessed 12 h post EGF-treatment,
as alterations in gene transcription are expected to precede
functional responses such as changes in ATP-induced Ca
2+
signaling and vimentin protein induction. EGF-mediated EMT
was confirmed by assessment of vimentin protein expression for all
samples at 24 h (data not shown). Fig. 5A shows the relative levels
of purinergic receptors in MDA-MB-468 cells in the absence and
presence of EGF treatment. In both groups high levels of P2X4
were detected, which was not altered by EGF. In both treatment
groups low to undetectable levels of mRNA were seen for P2X1,
P2X2, P2X3, P2X6, P2Y4, P2Y11, P2Y12, and P2Y14.
However, treatment with EGF did induce a switch in the suite
of purinergic ATP receptors including a 2.1-fold increase in P2Y6
mRNA and a 2.6-fold decrease in P2Y13 mRNA expression
Ca2+ Signaling and Purinergic Receptors in EMT
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EMT induction was seen for P2X5, where EGF induced a 4.6-fold
increase (Fig. 5B); suggesting that elevated P2X5 may be a
characterizing feature of the metastatic phenotype of some breast
cancer cells.
Given the magnitude of the increase in P2X5 in our model of
EMT, we assessed the consequence of P2X5 knockdown on EGF-
induced vimentin expression. We obtained a greater than 80%
knockdown of P2X5 mRNA in cells transfected with P2X5 siRNA
(siP2X5) relative to the non-targeting siRNA control (siNT)
Figure 1. EGF-induced EMT and receptor-mediated Ca
2+ signaling. MDA-MB-468 breast cancer cells were serum starved prior to treatment
with EGF (50 ng/mL) or control for 24, 72 or 120 h as depicted. A, representative panel of immunofluorescence (IF) images showing vimentin
expression (red) and DAPI nuclear staining (blue) following EGF stimulation (24 h). B, representative immunoblots for E-cadherin and vimentin
protein after treatment with EGF (left) and pooled data (right) quantified relative to b-actin loading control. Pooled values represent mean 6 S.D. for
6 pooled wells performed in triplicate in independent experiments. Statistical analysis was performed using two-way ANOVA with Bonferroni post-
tests and * signifies P,0.05. C, assessment of [Ca
2+]CYT in MDA-MB-468 cells treated with EGF (24 h) following stimulation with various concentrations
of either trypsin (PAR2 activation) or ATP (P2 receptor activation). Graphs represent the average dose response curves for measurement of peak
relative [Ca
2+]CYT for 9 wells from 3 independent experiments and are shown 6 S.D. Average EC50 values are shown inset and * represents the
significance for EC50 values, P,0.05, unpaired t-test.
doi:10.1371/journal.pone.0023464.g001
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significant (P,0.05) decrease in EGF-induced vimentin protein
expression (Fig. 5D).
P2X5 mRNA is significantly up-regulated in breast cancer cell
lines with mesenchymal characteristics and aggressive basal-like
clinical breast cancer samples.
To investigate the significance of P2X5 in breast cancer we
examined its expression in other models of EMT and in clinical
samples. We first compared P2X5 expression between the mesen-
chymal-like PMC42-ET breast cancer cell line and a derivative sub-
line PMC42-LA, which expresses epithelial-like markers [28]. P2X5
had a 13-fold higher expression in PMC42-ET cells relative to
PMC42-LA (Fig. 6A), further indicating an association with P2X5
and the metastatic phenotype. To investigate the distribution of
P2X5 in a panel of breast cancer cell lines of known transcriptional
subtype, we queried a microarray database of 24 human breast
cancer cell lines for P2X5 [29]. P2X5 was significantly enriched in
basal-like breast cancer cell lines compared to those of luminal origin
(Fig. 6B).Todetermine thepotential clinical relevance of thiscell line
data, we then examined a microarray gene expression dataset of 264
human breast cancer cases [30]. As we found with the cell lines,P2X5
was significantly overexpressed in tumors of the basal subtype
compared to the luminal A and B subtypes and ERBB2+ tumors
(Fig. 6C). Of the transcriptionally distinct breast cancer subtypes
defined by Perou et al [31], basal-like breast cancers are highly
aggressive, difficult to treat, and prone to metastasis. Furthermore
thesecancershavebeenlinkedtoEMTandaretranscriptionallyakin
to mesenchymal cells [32].
Discussion
Metastasis represents a major cause of mortality in women with
breast cancer [33], with EMT being increasingly investigated in this
context. Relatively few studies have investigated changes in cell
surface receptors that occur as a consequence of EMT, despite the
altered extracellular signals that would be encountered by a cell as it
metastasizes [34]. Using a model of EGF-induced EMT we
investigated two cell surface receptors that signal via alterations in
cytosolic calcium.Herewe reporta significant change inthe potency
ofATP-mediatedCa
2+signaling.Thiswasnotduetoanoverarching
change in cell signaling cascades as there was an absence of a similar
change observed in cells associated with PAR2 activation. In
addition to an altered potency of ATP, a change in the suite of
purinergic receptors was associated with EGF-induced EMT.
Alterations in responses to ATP as a consequence of EMT may
be reflective of purinergic receptor-regulated processes important
in tumor progression. ATP released via necrosis at the hypoxic
core of solid tumors, may serve as an important paracrine signal in
the tumor microenvironment [24]. Indeed, ATP signaling via
ionotropic P2X and metabotropic P2Y receptors regulates a range
of cellular events including proliferation, differentiation, apoptosis
Figure 3. Expression of vimentin protein and functional alterations in the response to ATP. A, MDA-MB-468 cells were serum starved and
treated with EGF for 1, 6, 12 and 24 h prior to measuring [Ca
2+]CYT with 1 mM ATP. Data are shown as the average relative [Ca
2+]CYT from 9 wells from
3 independent experiments. B, Representative immunoblot for vimentin protein after EGF treatment (left) and pooled data (right) normalized to the
b-actin loading control. Values represent the mean 6 S.D for 6 pooled wells from 3 independent isolations. Statistical analysis was performed using
two-way ANOVA and Bonferroni post-tests; * P,0.05.
doi:10.1371/journal.pone.0023464.g003
Figure 2. Effect of EGF treatment on the Ca
2+ response to ATP
stimulation. MDA-MB-468 cells were serum deprived and treated with
or without EGF for 24 h as depicted. A, average [Ca
2+]CYT transient in
cells stimulated with 1 mM ATP. B, [Ca
2+]CYT was assessed using 10 mM,
100 mM and 1 mM of ATP. Percent [Ca
2+]CYT recovery at the end of the
assay (800 s) is shown for each concentration of ATP and represent the
averages 6 S.D. of 9 wells from 3 independent experiments. Statistical
analysis was performed using two-way ANOVA with Bonferroni post-
tests; * signifies P,0.05.
doi:10.1371/journal.pone.0023464.g002
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therefore depend on the specific profile of cellular purinergic
receptors expressed. PC3 and DU-145 hormone refractory
prostate cancer cells, which have a similar expression profile
(P2X4,5,7, P2Y1,2,4,6) to estrogen and progesterone insensitive
MDA-MB-468 breast cancer cells, undergo growth inhibition in
response to ATP stimulation [36].
The kinetics and spatial characteristics of the Ca
2+ transient
dictate the activation of downstream signaling cascades and thus
cellular responses to agonist activation [15]. Our observation of a
change in the nature of the ATP-mediated cytosolic calcium
transient in addition to the rightward shift in the dose response
curve in cells treated with EGF is further evidence that altered
responses to ATP are a likely consequence of EGF-mediated
EMT.
In addition to altered Ca
2+ signaling to ATP with EMT, we also
report a change in the profile of purinergic receptors during the
transformation from an epithelial to a mesenchymal-like pheno-
type. This change in the suite of purinergic receptor transcription
was marked by a significant increase in P2X5, P2Y6 and a decrease
in P2Y13 expression. A change in the purinergic receptor isoform
profile is also seen during vascular remodeling [37]. Vascular
smooth muscle cells transitioning from the contractile to
proliferative (or synthetic) phenotype have reduced P2X1 levels
and an increase in P2Y1 and P2Y2 mRNA expression [38]. Our
results support that a remodeling of purinergic receptor transcrip-
tion occurs as a consequence of EMT although different
purinergic receptors are involved.
We investigated the potential significance of an increase in
P2X5 purinoceptors during EGF-induced EMT, as this isoform
was associated with the greatest alteration in purinergic expression
observed in this model. To study the consequence of changes in
P2X5 expression, we adopted a siRNA gene silencing approach to
knockdown P2X5 in this model of EGF-induced EMT. P2X5
silencing significantly reduced EGF-mediated induction of the
EMT marker vimentin. P2X5 receptors form functional homo-
meric trimers or may assemble into heteromultimers with P2X1
subunits [39,40]. As P2X1 mRNA was undetectable in this cell line
and underwent no apparent change in transcription with EGF-
stimulation, P2X5 subunits would most likely assemble into
homomeric ion channels in this cell-based model. Functional
P2X5 homomeric channels are permeable to calcium and
additionally display significant permeability to chloride ions and
the large organic ion NMDG [39]. Alterations in chloride ion
homeostasis occur in glioma cells and correlates with the invasive
phenotype [41].
P2X5 activation with ATP inhibits the proliferation of skeletal
muscle satellite cells and a role for P2X5 in the inhibition of cancer
cell proliferation is proposed [42]. Cancer cells at the invasive
front of solid tumors show a reduction in cell proliferation,
coinciding with an increase in cell migration and invasion [43,44].
A reduction in proliferation following ATP-mediated P2X5
activation may be an important mechanism in the switch from
an epithelial (proliferative) to a mesenchymal (migratory) pheno-
type during the process of EMT [45].
To determine if alterations in P2X5 transcription may be a
characterizing feature of some breast cancer cells associated with
a more mesenchymal phenotype we examined the level of P2X5
expression in a breast cancer cell line with epithelial character-
istics (PMC42-LA) compared to the parental mesenchymal cell
line PMC42-ET [28]. P2X5 was enriched in the mesenchymal
phenotype. This prompted us to investigate P2X5 expression in a
bank of human breast cancer cell lines classified as luminal or
basal by transcriptional profiling. P2X5 was upregulated in the
more invasive basal-like cell lines compared to luminal-like cell
lines. Assessment of P2X5 expression using microarray data from
264 human breast cancer samples classified as luminal (A/B),
ERBB2+ or basal, indicated that P2X5 is significantly upregu-
lated in the basal subset of clinical breast cancer samples
compared to all other subtypes. The basal molecular subtype
represents a subset of cancers that often express EMT-associated
markers [32], have a poor clinical prognosis and are often
associated with preferential metastasis to the lung and brain
[31,46]. The recently identified claudin-low intrinsic subtype of
breast cancers has similarities to basal-like breast cancers, are
triple negative and are enriched with EMT markers [47].
Figure 4. ATP signaling in non-adherent MDA-MB-468 cells
following EGF treatment. A, assessment of [Ca
2+]CYT in non-adherent
MDA-MB-468 cells treated with EGF (24 h) following stimulation with
various concentrations of ATP. Graphs represent the average dose
response curves for measurement of peak relative [Ca
2+]CYT and are
shown 6 S.D. The average EC50 values are shown inset and * represents
the significance for EC50 values; P,0.05, unpaired t-test. B, the average
[Ca
2+]CYT transient for suspended cells stimulated with 1 mM ATP. C,
Percent [Ca
2+]CYT recovery 6 S.D. at the end of the assay (800 s) was
assessed using 10 mM, 100 mM and 1 mM of ATP. Statistical analysis was
performed using two-way ANOVA with Bonferroni post-tests; * signifies
P,0.05. Values are representative of 12 wells from 3 independent
experiments.
doi:10.1371/journal.pone.0023464.g004
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type in breast cancer cell lines shows significant overlap with
highly malignant breast cancer stem cells isolated from clinical
subjects [48]. Future studies could further explore the role of
P2X5 in the mesenchymal phenotype by characterizing expres-
sion in the claudin-low subset of breast cancers and malignant
breast cancer stem cells. Future studies assessing the role of all the
purinergic receptors altered in MDA-MB-468 as a consequence
of EMT on intracellular calcium signaling and vimentin protein
induction would also be valuable.
In conclusion, the induction of EMT by EGF in MDA-MB-468
breast cancer cells is associated with alterations in the calcium
signaling response to ATP and results in a cellular phenotype with
an altered transcriptional profile of purinergic receptors, in
particular an upregulation of P2X5. Inhibition of P2X5 reduces
expression of the EMT marker vimentin and its increased
expression correlates with breast cancer cells that are associated
with a more mesenchymal phenotype.
Materials and Methods
Cell culture and EGF treatment
MDA-MB-468 human breast cancer cells [4] were maintained
in Dulbecco’s Modified Eagle’s Medium (D6546) supplemented
with 10% fetal calf serum (FCS), L-glutamine (4 mM), penicillin
100 U/mL and streptomycin 100 mg/mL (Sigma Aldrich). To
induce EMT, MDA-MB-468 cells were deprived of serum (0.5%
FCS) for 24 h and stimulated with EGF (50 ng/mL; Sigma
Aldrich) as previously described [4]. PMC42-ET and –LA human
breast cancer cells [28,49] were maintained in Roswell Park
Memorial Institute (RPMI)-1640 Medium (R8757, Sigma Aldrich)
supplemented with 10% FCS. Cultures were maintained in a
humidified incubator (37uC, 5% CO2) and were routinely
screened for mycoplasma contamination.
Immunofluorescence
MDA-MB-468 cells were seeded at 3610
4 cells per well in 96-
well black-walled imaging plates (BD Biosciences). After EGF
treatment cells were fixed with methanol-acetone (1:1). Mouse
anti-vimentin V9 Cy3-conjugated antibody (C9080, Sigma
Aldrich) was diluted 1:400 in phosphate buffered saline
supplemented with BSA (1% (w/v)) and incubated at 4uC
overnight [49]. Nuclear staining was performed using DAPI
(400 nM; Invitrogen) and incubated at room temperature for
1.5 h. Images were acquired using an ImageXpress Micro
automated epifluorescence microscope (Molecular Devices
Corporation).
Immunoblotting
Cell extracts were harvested as previously described [50] using
lysis buffer supplemented with protease inhibitors and phosphatase
inhibitors (Roche Applied Science). For gel electrophoresis,
samples were prepared using a reduced denatured protocol in
lithium dodecyl sulphate (LDS) 46 sample buffer (Invitrogen).
Approximately 20 mg of protein was loaded per well into a 4–12%
bis-tris gel (Invitrogen). The separated proteins were transferred
onto a polyvinylidene fluoride (PVDF) membrane (Invitrogen).
Mouse anti-vimentin V9 antibody (V6389, Sigma Aldrich) was
diluted to 1:750 [49] and mouse anti-E-cadherin (a kind gift from
Professor Alpha Yap, The University of Queensland, Australia)
was used 1:100. Anti-mouse horseradish peroxidase-conjugated
secondary antibody (170–6516, BioRad) was used at 1:10000. All
antibodies were prepared in 5% skim milk powder in PBST (0.1%
Tween-20). Images were acquired on a VersaDoc Imaging System
(BioRad) and quantified using ImageJ (v1.43u for Windows,
National Institutes of Health, USA). Protein density was
normalized to the b-actin (A5441, 1:10000, Sigma Aldrich)
loading control.
Measurement of intracellular Ca
2+
Calcium assays were performed with a fluorometric imaging
plate reader (FLIPR
TETRA, Molecular Devices Corporation) using
the no-wash PBX Ca
2+ Assay Kit (BD Biosciences) as previously
described [51]. For the measurement of intracellular Ca
2+ in
adherent cells, MDA-MB-468 cells were seeded at 3610
4 cells per
Figure 5. Effect of EGF on the transcriptional profile of purinergic receptors in MDA-MB-468 cells. Serum deprived MDA-MB-468 cells
were treated with EGF or control for 12 h prior to RNA isolation and real-time RT-PCR analysis. A, 2DCT values of all P2 receptors studied. Samples
with a CT outside the limit of detection were assigned a value of 35 (& signifies target registered above the limit of detection (CT.35) in one or more
samples for both EGF and control treatments;N denotes target was above the limit of detection in EGF samples only). B, Quantitation of alterations in
P2X5 mRNA following EGF treatment (12 h). C, Knockdown efficiency of P2X5 siRNA (siP2X5) relative to the non-targeting control (siNT) was assessed
using real time RT-PCR; representative of 5 wells from 3 independent experiments. D, EGF-induced vimentin protein expression (IF) in MDA-MB-468
cells treated with siNT or siP2X5. Results are representative of 9 wells from 3 independent experiments (unless otherwise specified) and are shown
with S.D. (* P,0.05, unpaired t-test).
doi:10.1371/journal.pone.0023464.g005
Ca2+ Signaling and Purinergic Receptors in EMT
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23464well in 96-well black-walled imaging plates (Corning) and treated
with EGF. For the measurement of intracellular Ca
2+ in
suspended cells, cells were treated with EGF, trypsinized and
resuspended in DMEM containing FCS (0.5%), BSA (0.3%) and
Fluo-4 AM Ca
2+ indicator (2 mM). Cells were incubated in
centrifuge tubes for 60 min at 37uC. Following dye uptake, cells
were centrifuged and resuspended in physiological salt solution
(PSS) buffer. Suspended cells were seeded in 96-well black-walled
plates at a density of 6.15610
4 cells per well. Intracellular Ca
2+
measurements were performed with an excitation intensity of 470–
495 nm and a 515–575 nm emission filter. Fluorescent values





Cells were plated at 8.5610
5 cells per well in a 6-well plate (P2
purinergic screen) or from a 96 well plate (P2X5 studies) and cells
were treated with EGF. Total RNA was isolated using the RNeasy
kit (Qiagen) as per the manufacturer’s instructions. RNA was
reverse transcribed (Qiagen Omniscript RT Kit) and amplified
using TaqMan Custom Array plates spotted with a selection of
purinergic receptor assays (Table S1) and TaqMan Universal
Master Mix (Applied Biosystems). Reactions were cycled with
universal cycling conditions and a StepOnePlus Real Time PCR
System (Applied Biosystems). Relative quantification was deter-
mined with reference to 18s ribosomal RNA and analyzed using
the comparative Ct method as previously described [52].
Figure 6. Expression of P2X5 in breast cancer cell lines and clinical samples. A, quantitation of P2X5 mRNA in PMC42-ET (mesenchymal)
breast cancer cells relative to PMC42-LA (epithelial-like) breast cancer cells; * P,0.05, unpaired t-test. B, Relative P2X5 expression was examined using
microarray data from 24 human breast cancer cell lines classified as luminal or basal via transcriptional profiling. A Mann-Whitney test was used for
assessing statistical significance (*P,0.05). C, Evaluation of P2X5 levels in 264 human breast cancer samples representing four transcriptional
subtypes. Statistical analysis was performed using Kruskall-Wallis test with Dunn’s post-test and * signifies P,0.05. Horizontal lines represent the
median value for each cluster.
doi:10.1371/journal.pone.0023464.g006
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Breast cancer cell lines were cultured in 2D and analyzed using
Affymetrix microarrays as previously described [29]. This panel of
cell lines included 13 luminal-type (600MPE, BT474, BT483,
CAMA1, MCF7, MDA-MB-361, MDA-MB-415, MDA-MB-453,
SKBR3, T47D, UACC812, ZR751 and ZR75B) and 11 basal-
type cell lines (BT549, HMT3522-S1, HMT3522-T4-2,
HCC1500, HCC1569, HCC70, HS578T, MCF12A, MDA-MB-
231, MDA-MB-436 and MDA-MB-468). All cell lines were
acquired from ATCC, except HMT3522-S1 [53] and HMT3522-
T4-2 [54] which are available from Sigma Aldrich. P2X5
expression was assessed using the probe 210448_s_at. We also
mined microarray data from 295 breast cancer cases [30]. We
excluded the 31 samples in this dataset annotated as ‘‘normal-like’’
as these contain a substantial proportion of contaminating non-
neoplastic cells, and focused on the 264 tumors annotated as either
basal, ERBB2+ and luminal A or B. MIAME-compliant raw
microarray data are available from the following sources:
ArrayExpress E-TABM-244 (cell lines) and NCBI GEO
GSE2845 (tumors).
siRNA transfection
For all siRNA experiments, cells were cultured in antibiotic free
media. MDA-MB-468 cells were plated at a seeding density of
5610
3 cells per well in a 96-well plate. siRNA transfection was
performed with Dharmacon ON-TARGETplus SMARTpool
TM
siRNA (100 nM), comprising a pool of 4 siRNA sequences
rationally designed with dual strand modification and use of an
algorithm to reduce seed region matches. DharmaFECT4
transfection reagent was used (0.1 mL/well) as per the manufac-
turer’s instructions. Cells were serum starved 48 h post-transfec-
tion. At 72 h post-transfection cells were stimulated with EGF or
control for 24 h prior to fixing and staining for vimentin
expression. For all studies, successful knockdown (.80%) was
confirmed at the transcriptional level 72 h post-transfection. The
following Dharmacon siRNAs were used in this study: On-
TARGETplus SMARTpool
TM nontargeting siRNA (D-001810-
10-05) and On-TARGETplus SMARTpool
TM P2X5 siRNA (L-
006286-00-0005).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 5.04 for Windows unless otherwise stated. Specific
statistical tests used are described in each figure legend.
Supporting Information
Table S1 TaqMan Assay IDs for the panel of P2
purinergic assays used for real-time RT-PCR.
(PDF)
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